Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Similar documents
3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

Diagnosis, pathology and prognosis including variant pathology

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

Update on Reporting Prostate Cancer Pathology

Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Although current American Cancer Society guidelines

Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)

GUIDELINES ON PROSTATE CANCER

A re-audit of Prostate biopsies from January to December 2010 and 2013.

Prostatic ductal adenocarcinoma is a subtype of

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

Prostate Overview Quiz

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Supplemental Information

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Prostate Case Scenario 1

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Recommendations for the Reporting of Prostate Carcinoma

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Outline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

They Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples

TOPICS FOR DISCUSSION

ASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of

PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Standards and Datasets for Reporting Cancers. Dataset for histopathology reports for prostatic carcinoma (2 nd edition) October 2009

2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT

The Role of the Pathologist Active Surveillance for Prostate Cancer

GUIDELINEs ON PROSTATE CANCER

Chapter 2. Understanding My Diagnosis

Ductal adenocarcinoma of the prostate: A clinicopathological study

ISPUB.COM. Interpretation Of Prostatic Biopsies: A Review. A Chitale, S Khubchandani INTRODUCTION NON-NEOPLASTIC LESIONS GRADING: GLEASON'S SCORE

OMPRN Pathology Matters Meeting 2017

3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:

A215- Urinary bladder cancer tissues

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

5/21/2018. Difficulty in Underdiagnosing Prostate Cancer. Diagnosis of Prostate Cancer. Evaluation of Prostate Cancer and Atypical on Needle Biopsy

Large blocks in prostate and bladder pathology

Prognostic value of the Gleason score in prostate cancer

ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Carcinoma of the Urinary Bladder Histopathology

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Clinicopathological Features of Prostate Ductal Carcinoma: Matching Analysis and Comparison with Prostate Acinar Carcinoma

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens

Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity

Prostate MRI for local staging and surgical planning in prostate cancer

20 Prostate Cancer Dan Ash

Definition of Synoptic Reporting

Kidney Case 1 SURGICAL PATHOLOGY REPORT

Pathology of the Prostate. PathoBasic Tatjana Vlajnic

Prostate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue

Prostate cancer grading: a decade after the 2005 modified system

Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy

Definition Prostate cancer

Protocol for the Examination of Biopsy Specimens From Patients With Carcinoma of the Prostate Gland

Papillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.

Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)

ROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Post Neoadjuvant therapy: issues in interpretation

Grading Prostate Cancer: Recent Changes and Refinements

In 2005, International Society of Urological Pathology

A schematic of the rectal probe in contact with the prostate is show in this diagram.

VULVAR CARCINOMA. Page 1 of 5

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Case Scenario 1: Breast

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

Uropathology January Jon Oxley

3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours

Boot Camp Case Scenarios

Penile cancer teams in UK. Common variants. Penile cancer teams. Basaloid squamous carcinoma. The Pathology of Penile Tumours

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

Large Colorectal Adenomas An Approach to Pathologic Evaluation

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Prostate Cancer. David Wilkinson MD Gulfshore Urology

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of

Pancreatobiliary Frozen Section Nightmares

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

OPEN ACCESS ORIGINAL ARTICLE

Disclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose

Transcription:

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital

Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed of neoplastic epithelial cells with secretory differentiation, arranged in a variety of histomorphological patterns, including glands, cords, single cells, sheets. Basal cells are absent. 2 2

Prostate cancer How do pathologists diagnose prostate cancer? Core biopsy Transurethral resection Radical prostatectomy What are important pathological parameters that impact prognosis? 3 3

Prostate. Benign acini Acinar adenocarcinoma. Malignant acini p63/34βe12 p63/34βe12 4 Basal cells No basal cells

Diagnosis of prostate cancer Architecture, at low magnification Defines Gleason grade Cytonuclear features, at high magnification Absence of basal cells, corroborated using immunohistochemistry 5 5

Prostate Cancer: Gleason grade Developed by Dr Donald Gleason in 1966-1974 Based on glandular pattern of tumour identified at low magnification (architecture) Sum of the 2 most common grade patterns

Prostate Cancer: Gleason grade In tumours with 2 distinct histologic patterns, number of observed deaths fell between that expected based on the primary (most common) & that of the secondary (2 nd most common) patterns. Combined Gleason grade = Gleason score (sum). Primary Gleason pattern + secondary Gleason pattern = Gleason score. 7

Gleason Grading System Gleason 1 Gleason 2 Gleason 3 Gleason 4 Gleason 5

Prostate Cancer: Gleason grade Gleason score of 2 to 4 : low grade. Gleason score of 5 to 7* : intermediate grade. Gleason score of 8 to 10 : high grade. * Gleason score 7 tumours more aggressive than Gleason 5 to 6. 9

Convened because: Evolution of medical practice and changes in diagnosis of prostate cancer since 1966. Advent of prostate cancer screening. Availability of serum PSA. Use of thin biopsy needles, allowing wider sampling of the prostate. Increasing numbers of radical prostatectomies. Application of immunohistochemistry. Recognition of variants of prostate cancer.

Further modification of Gleason system ~ Deficiencies in the original Gleason system have impacted on patient care. Gleason score 7 can be derived from Gleason 3+4 or Gleason 4+3. Lowest combined grade assigned is 6 on a scale of 2 to 10, leading to patients incorrectly assuming that they have a more aggressive cancer when they have good prognostic disease. WHO 2016

Prostate Cancer: Grade groups Grade group 1 ~ Gleason score 6 Only individual discrete well formed glands. Grade group 2 ~ Gleason score 3+4=7 Predominantly well-formed glands with lesser component of poorly formed/fused/cribriform glands. Grade group 3 ~ Gleason score 4+3=7 Predominantly poorly formed/fused/cribriform glands with lesser component of well-formed glands. Grade group 4 ~ Gleason score 4+4=8; 3+5=8; 5+3=8 Poorly formed/fused/cribriform glands. Predominantly well-formed glands and lesser component lacking glands. Predominantly lacking glands and lesser component of well-formed glands. Grade group 5 ~ Gleason scores 9-10 Lack gland formation (or with necrosis) with or without poorly formed/fused/cribriform glands. 12

Core biopsy Radical prostatectomy 13 Epstein et al

Core biopsy Radical prostatectomy J Clin Pathol. 2017 Sep;70(9):745-753. 14

Cytonuclear features Prostate cancer p63/34βe12 15 Absence of basal cells

Prostate cancer: Adenocarcinoma variants Prostatic duct adenocarcinoma Periurethral prostatic ducts, exophytic lesion into urethra, around verumontanum Aggressive, less responsive to hormones Mucinous adenocarcinoma Aggressive, bone metastases, advanced disease Neuroendocrine differentiation Small cell carcinoma: aggressive Prostatic duct adenocarcinoma Mucinous adenocarcinoma Small cell carcinoma Acinar adenocarcinoma with NE differentiation

Pathologic evaluation of prostate cancer Types of prostatic surgical/biopsy specimens: Needle biopsies (TRUS, transperineal). Transurethral resection (TURP). Radical prostatectomy. 17

Prostate Needle Biopsy: 10 core method, labelled cores

Prostate Needle Biopsy: Core Localisation

Pathologic handling of prostatic needle biopsies Location of positive biopsy cores: Predictive of adverse findings at radical prostatectomy. Cancer in multiple biopsy cores predicts multifocal cancer. 20

Pathologic handling of prostatic needle biopsies Location of biopsy cores: Rebiopsy techniques following a diagnosis of atypical glands suspicious for cancer. Increased number of rebiopsy cores from the original and adjacent sites of initial atypical biopsy. Cancer found on rebiopsy in the same site as the initial atypical biopsy in 48% of men (Allen et al. Urology 1998;52:803-807). 21

1 st biopsy Repeat biopsy Atypical glands suspicious of cancer in core 9 Cancer in core 10 34 E12

Prostate needle biopsies: histologic parameters of importance Gleason score/grade group. Tumour quantum: No. of positive cores. Total mm among all cores. %age of each core with cancer. Total % of cancer in entire specimen. Fraction of positive cores. For Gleason score 7, to provide the % Gleason pattern 4. Perineural invasion: Correlation with extraprostatic extension on RP. Higher incidence of disease progression following RT and RP. 23

Prostate needle biopsies: grading of cancer Gleason score 2 to 4? (Am J Surg Pathol 2000; 24: 477-8) 24

Transurethral resection of prostate Incidental discovery of prostate cancer in 8% to 10% cases. Transition zone or large peripheral zone cancers. Sampling of transurethral resection specimens: Initial random submission of tissue in 8 cassettes: Identifies almost all T1b cancers & about 90% of T1a cancers. Submission of all tissue in younger men (<65 yrs). Remaining tissue submitted if T1a cancer found in the initial 8 cassettes. 25

Transurethral resection of prostate T1a cancer in younger men: increased progression risk with long-term follow-up. definitive therapy an option. Submission of remaining tissue if T1a cancer found: potential of upstaging based on high-grade cancer being found in the additionally submitted tissue. T1a : tumour occupies 5% of the specimen & Gleason sum< 7 T1b: higher volume OR higher grade tumour

Radical Prostatectomy Complete vs partial sampling: 12% pathologists sample entire prostate gland. Whole mount vs routine sections. Sections required: Apex (distal margin) Base (proximal margin) Seminal vesicles (base) Vas deferens Rest of prostate gland 27

Handling of prostatic surgical specimens: Radical Prostatectomy Whole mount sections: Aesthetically pleasing. Suitable for teaching and publications. Correlation with imaging techniques. Disadvantages: Thick sections Technically demanding Storage problems 28

A B C distal Radical prostatectomy: whole mount sections with cancer foci mapping D E proximal F

Radical Prostatectomy Detailed mapping of prostate cancer foci: Biopsies targeted to areas of highest tumour concentration. Optimise locally directed therapies for prostate cancer. Correlation with radiology. 31

Radical Prostatectomy: Pathologic parameters Gleason score (grade group). Extraprostatic extension. Seminal vesicle invasion. Lymph node metastases. Surgical margin status. Perineural invasion. Tumour volume. Lymphovascular invasion. Pathologic stage 32

Radical Prostatectomy: extraprostatic extension Tumour extends beyond the outer condensed smooth muscle of the prostate. Focal vs established: Focal: only a few glands outside the prostate. Established: non-focal. 33 Focal EPE Established EPE

Radical Prostatectomy: seminal vesicle invasion Cancer invades muscle coat of the seminal vesicle. Significant prognostic indicator. Seminal vesicle Cancer in the muscular wall 34

Radical Prostatectomy: lymph node metastases Uniformly poor prognosis in presence of nodal metastases. 1% to 2% of patients undergoing RP. Diameter of tumour in node. 35

Radical Prostatectomy: surgical margin status Positive surgical margins an important prognostic parameter following surgery. Equivocal, focal or extensive. Site of positive surgical margin is often the site of EPE. Positive surgical margin can result from incision into the gland without EPE. Record length of positive margins add all the lengths of positive margins. Threshold of 3mm to separate focal vs nonfocal/extensive involvement of margins. Report grade of tumour at margin. 36

Positive surgical margins in a radical prostatectomy 34 E12

Radical Prostatectomy: perineural invasion Found in 75% to 84% of RP. Not independently prognostic. Largest diameter of nerve with perineural invasion independently related to an increased likelihood of biochemical failure after RP. (Maru et al. Hum Pathol 2001; 32: 828-33) Not necessary to report its presence. 38

Radical Prostatectomy: tumour volume Total tumour volume is an important predictor of prognosis. Not independently prognostic when adjusted for pathologic stage, grade and surgical margins. Maximal dimension of tumour in the largest tumour slice. 39

Radical Prostatectomy: lymphovascular invasion Important in univariate analysis. Independent prognostic utility? 40

ISUP consensus conference on handling and staging of radical prostatectomy specimens WG1: Specimen handling (Mod Pathol 2011; 24: 6-15). WG2: T2 substaging and prostate cancer volume (Mod Pathol 2011; 24: 16-25). WG3: Extraprostatic extension, lymphovascular invasion and locally advanced disease (Mod Pathol 2011; 24: 26-38). WG4: Seminal vesicles and lymph nodes (Mod Pathol 2011; 24: 39-47). WG5: Surgical margins (Mod Pathol 2011; 24: 48-57). 41

SUMMARY ~ Pathologic evaluation of prostate cancer Accurate reporting of pathologic parameters of importance in different prostate specimens. Familiarity with histologic features of cancer. Awareness of pitfalls and benign mimics. Use of adjunctive diagnostic tools eg. immunohistochemistry. 42

43 43